1. Home
  2. SION vs ESPR Comparison

SION vs ESPR Comparison

Compare SION & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SION
  • ESPR
  • Stock Information
  • Founded
  • SION 2019
  • ESPR 2008
  • Country
  • SION United States
  • ESPR United States
  • Employees
  • SION N/A
  • ESPR N/A
  • Industry
  • SION
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • SION
  • ESPR Health Care
  • Exchange
  • SION NYSE
  • ESPR Nasdaq
  • Market Cap
  • SION 338.0M
  • ESPR 305.0M
  • IPO Year
  • SION 2025
  • ESPR 2013
  • Fundamental
  • Price
  • SION $11.07
  • ESPR $0.95
  • Analyst Decision
  • SION Strong Buy
  • ESPR Buy
  • Analyst Count
  • SION 1
  • ESPR 7
  • Target Price
  • SION $32.00
  • ESPR $6.07
  • AVG Volume (30 Days)
  • SION 225.5K
  • ESPR 5.5M
  • Earning Date
  • SION 05-25-2025
  • ESPR 05-06-2025
  • Dividend Yield
  • SION N/A
  • ESPR N/A
  • EPS Growth
  • SION N/A
  • ESPR N/A
  • EPS
  • SION N/A
  • ESPR N/A
  • Revenue
  • SION N/A
  • ESPR $332,314,000.00
  • Revenue This Year
  • SION N/A
  • ESPR $5.17
  • Revenue Next Year
  • SION N/A
  • ESPR N/A
  • P/E Ratio
  • SION N/A
  • ESPR N/A
  • Revenue Growth
  • SION N/A
  • ESPR 185.66
  • 52 Week Low
  • SION $7.26
  • ESPR $0.93
  • 52 Week High
  • SION $25.19
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • SION N/A
  • ESPR 22.73
  • Support Level
  • SION N/A
  • ESPR $0.93
  • Resistance Level
  • SION N/A
  • ESPR $1.06
  • Average True Range (ATR)
  • SION 0.00
  • ESPR 0.09
  • MACD
  • SION 0.00
  • ESPR -0.02
  • Stochastic Oscillator
  • SION 0.00
  • ESPR 3.57

About SION SIONNA THERAPEUTICS INC

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: